Intuitive Surgical, Inc. (NASDAQ:ISRG) Position Lessened by Hancock Whitney Corp

Hancock Whitney Corp reduced its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,323 shares of the medical equipment provider’s stock after selling 534 shares during the quarter. Intuitive Surgical comprises approximately 0.8% of Hancock Whitney Corp’s holdings, making the stock its 26th largest position. Hancock Whitney Corp’s holdings in Intuitive Surgical were worth $23,721,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Gilbert & Cook Inc. increased its holdings in shares of Intuitive Surgical by 6.5% in the 4th quarter. Gilbert & Cook Inc. now owns 3,437 shares of the medical equipment provider’s stock worth $1,160,000 after acquiring an additional 211 shares during the period. TrinityPoint Wealth LLC grew its position in Intuitive Surgical by 21.5% in the 4th quarter. TrinityPoint Wealth LLC now owns 1,081 shares of the medical equipment provider’s stock worth $365,000 after purchasing an additional 191 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Intuitive Surgical by 7.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 854 shares of the medical equipment provider’s stock valued at $288,000 after purchasing an additional 62 shares during the period. Ontario Teachers Pension Plan Board raised its holdings in shares of Intuitive Surgical by 3.7% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 3,062 shares of the medical equipment provider’s stock valued at $1,033,000 after buying an additional 109 shares during the last quarter. Finally, US Bancorp DE raised its holdings in shares of Intuitive Surgical by 12.7% during the fourth quarter. US Bancorp DE now owns 69,919 shares of the medical equipment provider’s stock valued at $23,588,000 after buying an additional 7,880 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Trading Down 0.8 %

Shares of ISRG opened at $486.20 on Friday. The business’s 50-day moving average price is $468.01 and its 200 day moving average price is $424.86. The stock has a market capitalization of $172.46 billion, a P/E ratio of 87.76, a P/E/G ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period last year, the firm posted $1.18 earnings per share. On average, research analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In related news, Director Craig H. Barratt sold 1,400 shares of the stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Intuitive Surgical news, EVP Myriam Curet sold 2,818 shares of Intuitive Surgical stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the completion of the sale, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $136,522.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $641,382.00. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock valued at $25,528,753 in the last three months. 0.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on ISRG shares. The Goldman Sachs Group began coverage on Intuitive Surgical in a research report on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price on the stock. Citigroup raised their price target on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. JPMorgan Chase & Co. upped their price objective on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Truist Financial increased their target price on shares of Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Finally, Morgan Stanley boosted their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $446.45.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.